Food News and Research

RSS

Particle beam radiation therapy for cancer cure is better than traditional radiation method

Particle beam radiation therapy, a technology used to treat several types of cancer, is considered by some clinicians to be better than traditional radiation, but there is limited evidence about its safety compared with other types of radiation therapy, according to a new comparative effectiveness report funded by HHS' Agency for Healthcare Research and Quality.

15 Sep 2009

Medtronic informs physicians about the incorrect labeling of current SC catheter

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified its letters to physicians related to the incompatibility of its Sutureless Connector (SC) intrathecal catheters with the IsoMed constant-flow infusion pumps as a Class I recall.

15 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

CTIA issues statement on the health effects of mobile usage

Today, CTIA-The Wireless Association® President and CEO Steve Largent issued the following statement in response to the U.S. Senate Subcommittee on Appropriations for the Departments of Labor, Health and Human Services, Education, and Related Agencies Hearing on “The Health Effects of Cell Phone Use:”

15 Sep 2009

Mellow Hope completes clinical trial of H1N1 vaccine, receives approval from SFDA

At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.

15 Sep 2009

Prebiotic Inulin fiber supplement from Standard Process

Our gut is home to different types of bacteria, many of which live in harmony with us. Maintaining a balance of helpful bacteria within the gut is important for the health of several body functions. To help provide a favorable environment for friendly microbes to thrive, Standard Process Inc.® proudly introduces its newest product, Prebiotic Inulin.

15 Sep 2009

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

FDA provides a complete response letter for Digestive Care's PANCRECARB

Digestive Care, Inc. (DCI) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) and has moved closer to obtaining approval of its New Drug Application (NDA) for PANCRECARB((R) )(pancrelipase) used for the treatment of Exocrine Pancreatic Insufficiency.

15 Sep 2009

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

15 Sep 2009

FDA clears Diagnostic HYBRIDS' D3 FastPoint L-DFA Respiratory Virus Identification Kit

Diagnostic HYBRIDS, a leading developer of IVD fluorescent staining kits and cell culture products, today announced the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Respiratory Virus Identification Kit, which allows the individual detection of influenza A, influenza B, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), adenovirus and parainfluenza viruses from a patient’s specimen in under 30 minutes.

15 Sep 2009

Common pain cream could serve as cardiac-protectant during heart attack: Study

New research from the University of Cincinnati (UC) shows that a common, over-the-counter pain salve rubbed on the skin during a heart attack could serve as a cardiac-protectant, preventing or reducing damage to the heart while interventions are administered.

15 Sep 2009

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.

14 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Blue Care Network reaches milestone: Enrolls 100,000 members for Healthy Blue Living

Blue Care Network of Michigan's innovative wellness product, Healthy Blue Living, which rewards individuals for committing to healthy lifestyles, reached the 100,000 member benchmark in less than three years.

14 Sep 2009

Protalix Biotherapeutics reports completion of its Phase III trial of prGCD

Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.

14 Sep 2009

Food preparation methods may put Canadians at risk of liver disease

As we head into the winter months, when locally grown food is less available and our fresh foods have to be imported, do you know just how far your food has travelled and what it may have picked up along the way?

14 Sep 2009

FDA approves St. Jude Medical's EnSite Velocity Cardiac Mapping System

St. Jude Medical, Inc. (NYSE: STJ) today announced U.S. Food and Drug Administration (FDA) clearance and U.S. launch of its EnSite Velocity™ Cardiac Mapping System. This new system has been designed to help physicians more efficiently diagnose and guide therapy to treat abnormal heart rhythms.

14 Sep 2009

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular carcinoma (commonly referred to as primary liver cancer) and Celsion’s on-going ThermoDox Phase III global HEAT clinical study.

14 Sep 2009

Food News and Research

Particle beam radiation therapy for cancer cure is better than traditional radiation method

Medtronic informs physicians about the incorrect labeling of current SC catheter

Phase III results of Lauriad presented at the 49th Annual ICAAC

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

CTIA issues statement on the health effects of mobile usage

Mellow Hope completes clinical trial of H1N1 vaccine, receives approval from SFDA

Prebiotic Inulin fiber supplement from Standard Process

Public health policy should stress on reduction in sodium intake

FDA provides a complete response letter for Digestive Care's PANCRECARB

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

Third-quarter fiscal 2009 results announced by DiagnoCure

FDA clears Diagnostic HYBRIDS' D3 FastPoint L-DFA Respiratory Virus Identification Kit

Common pain cream could serve as cardiac-protectant during heart attack: Study

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Blue Care Network reaches milestone: Enrolls 100,000 members for Healthy Blue Living

Protalix Biotherapeutics reports completion of its Phase III trial of prGCD

Food preparation methods may put Canadians at risk of liver disease

FDA approves St. Jude Medical's EnSite Velocity Cardiac Mapping System

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Understanding cultivated meat and its global potential eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News